lunes, 28 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

View original at finance.yahoo.com
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tic…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BRAVECTO QUANTUM is the longest-lasting flea and tick protection available for dogs in the United States

    60% confidence

  • Asian longhorned and Gulf Coast ticks continue to expand geographically and present risks to canine health

    60% confidence

  • The flea lifecycle can last as long as 12 weeks, and monthly treatments may leave gaps in protection

    60% confidence

  • BRAVECTO QUANTUM delivers the longest-lasting protection available in a single dose, now covering an even broader range of clinically important tick species

    60% confidence

  • Safety was demonstrated when BRAVECTO QUANTUM was dosed at 5 times the recommended dose every 4 months for a total of 6 doses

    60% confidence

  • Fleas and ticks are not only active in the spring and summer months and are a year-round risk

    60% confidence

  • For more than a decade, BRAVECTO has set the benchmark for extended-duration flea and tick protection

    60% confidence

  • Fleas are the most common external parasite found on pets

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs — Source | Via News | es.VIA.NEWS